logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
02/05/2025
Pivotal Research: Lowering the target price for META from $875 to $830.
Latest
2 m ago
According to the AI Flash News, Pacific Securities released a research report on May 2, giving a buy rating to Junshi Biosciences (688180.SH). The reasons for the rating mainly include: 1) Expanded sales revenue maintains high growth, significant improvement in operational efficiency, and cash on hand of 3 billion yuan; 2) Junshi obtained 12 indications domestically and made smooth progress in international layout; 3) Two early pipeline products entered clinical stages, with VV116 being conditionally approved for regular approval; 4) The core pipeline in 2025 has multiple catalysts. (Daily Economic News)
2 m ago
AI Express News, on May 2, Pacific Securities issued a research report giving Haitai New Light (688677.SH) a buy rating. The main reasons for the rating include: 1) Customer order cycle is improving, with the full year expected to see a recovery in growth; 2) Strengthened supply capabilities in multiple regions, further deepening cooperation with major customers; 3) Slight improvement in gross profit margin, with net profit margin stabilizing. (Daily Economic News)
2 m ago
According to an AI flash news, Tianfeng Securities released a research report on May 2nd, giving Huari Group (300979.SZ) a buy rating. The rating reasons mainly include: 1) New customers and deeper cooperation with existing customers are important guarantees for stable and healthy growth of performance; 2) Adjusting strategies in a timely manner based on tariffs. (Daily Economic News)
2 m ago
According to the AI Quick Report of Every Economy, Pacific released a research report on May 2, giving a buy rating to Ren Fu Medicine (600079.SH). The main reasons for the rating include: 1) The core subsidiary business continues to maintain steady growth; 2) Open a new strategic synergy journey with China Merchants Group. (Daily Economic News)
2 m ago
Every AI Express, Pacific Securities released a research report on May 2, giving Ganli Pharmaceutical (603087.SH) a buy rating. The main reasons for the rating include: 1) Rapid growth in domestic revenue in 2025Q1, with sales and price growth effects synergistically apparent; 2) Continued expansion of overseas business, with positive results in multiple locations; 3) Gross margin rebound, net profit margin increase affected by financial assets. (Daily Economic News)
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.